1 – 50 of 88
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
[18F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes
(
- Contribution to journal › Article
-
Mark
Impact of simulated reduced injected dose on the assessment of amyloid PET scans
2023) In European Journal of Nuclear Medicine and Molecular Imaging(
- Contribution to journal › Article
-
Mark
Tau pathology as determinant of changes in atrophy and cerebral blood flow : a multi-modal longitudinal imaging study
(
- Contribution to journal › Article
-
Mark
Automated quantification of PET/CT skeletal tumor burden in prostate cancer using artificial intelligence : The PET index
(
- Contribution to journal › Article
-
Mark
Investigation of a CZT-based hand-held gamma-camera for pre-clinical imaging of alpha-emitter 225Ac
2023) Annual Congress of the European Association of Nuclear Medicine In European Journal of Nuclear Medicine and Molecular Imaging 50(Suppl 1). p.129-129(
- Contribution to journal › Published meeting abstract
-
Mark
Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Quantification of amyloid PET for future clinical use : a state-of-the-art review
(
- Contribution to journal › Scientific review
-
Mark
Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians
(
- Contribution to journal › Article
-
Mark
Analytical performance of aPROMISE : automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting
(
- Contribution to journal › Article
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
(
- Contribution to journal › Article
-
Mark
Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease
(
- Contribution to journal › Article
- 2021
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
(
- Contribution to journal › Article
-
Mark
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
(
- Contribution to journal › Article
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
(
- Contribution to journal › Article
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
(
- Contribution to journal › Scientific review
-
Mark
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers : methodological update
(
- Contribution to journal › Article
-
Mark
Impact of the COVID-19 pandemic on nuclear medicine departments in Europe
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
-
Mark
Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults
2020) In European Journal of Nuclear Medicine and Molecular Imaging(
- Contribution to journal › Article
-
Mark
Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Letter to editor
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
(
- Contribution to journal › Article
- 2019
-
Mark
Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
A guide for a brave future for lung ventilation/perfusion tomography : the most important pulmonary nuclear medicine technique
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma
(
- Contribution to journal › Article
- 2018
-
Mark
EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations
(
- Contribution to journal › Article
-
Mark
From fixed activities to personalized treatments in radionuclide therapy : lost in translation?
(
- Contribution to journal › Article
- 2017
-
Mark
The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy
(
- Contribution to journal › Article
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
-
Mark
The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer
(
- Contribution to journal › Article
-
Mark
The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma
(
- Contribution to journal › Article
- 2016
-
Mark
Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption.
(
- Contribution to journal › Article
- 2015
-
Mark
V/P SPECT as a diagnostic tool for pregnant women with suspected pulmonary embolism.
(
- Contribution to journal › Article
-
Mark
MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
(
- Contribution to journal › Article
-
Mark
EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision
(
- Contribution to journal › Article
-
Mark
Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer.
2015) In European Journal of Nuclear Medicine and Molecular Imaging(
- Contribution to journal › Article
- 2014
-
Mark
Good clinical practice in pulmonary embolism diagnosis: where do we stand today?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule
(
- Contribution to journal › Article
- 2013
-
Mark
Improved quantification of small hearts for gated myocardial perfusion imaging
(
- Contribution to journal › Article
-
Mark
Perfusion SPECT in patients with suspected pulmonary embolism.
(
- Contribution to journal › Article